STUDY DESIGN: Cohort study of subjects with insertional Achilles tendinopathy (IAT). OBJECTIVES: The purpose of this study was to establish the minimum clinically important difference (MCID) on the Victorian Institute of Sport Assessment - Achilles Questionnaire (VISA-A) and the Lower Extremity Functional Scale (LEFS) for patients with IAT. BACKGROUND: The VISA-A and LEFS are two measures commonly utilized for patients with IAT. Previous authors have estimated the MCID for the VISA-A, but a MCID has not been formally established. The MCID for the LEFS has been established for patients with lower extremity conditions in general, but it is not clear if this MCID is applicable to patients with IAT. METHODS:Fifteen subjects participating in a randomized controlled trial studying the effectiveness of intervention for IAT over a 12-week period were included in this study. Subjects completed the VISA-A and LEFS forms at baseline and 12 weeks after the initiation of treatment. All subjects also completed a 15-point global rating of change (GROC) questionnaire at 12 weeks after the initiation of treatment. Subjects were classified as improved or stable based on their GROC scores. RESULTS: The area under the curve (AUC) for the VISA-A was 0.97 and a MCID of 6.5 points was identified. The AUC for the LEFS was 0.97 and a MCID of 12 points was identified. CONCLUSION: The VISA-A and LEFS are both useful outcome measures to assess response in patients with IAT. LEVEL OF EVIDENCE: 3.
RCT Entities:
STUDY DESIGN: Cohort study of subjects with insertional Achilles tendinopathy (IAT). OBJECTIVES: The purpose of this study was to establish the minimum clinically important difference (MCID) on the Victorian Institute of Sport Assessment - Achilles Questionnaire (VISA-A) and the Lower Extremity Functional Scale (LEFS) for patients with IAT. BACKGROUND: The VISA-A and LEFS are two measures commonly utilized for patients with IAT. Previous authors have estimated the MCID for the VISA-A, but a MCID has not been formally established. The MCID for the LEFS has been established for patients with lower extremity conditions in general, but it is not clear if this MCID is applicable to patients with IAT. METHODS: Fifteen subjects participating in a randomized controlled trial studying the effectiveness of intervention for IAT over a 12-week period were included in this study. Subjects completed the VISA-A and LEFS forms at baseline and 12 weeks after the initiation of treatment. All subjects also completed a 15-point global rating of change (GROC) questionnaire at 12 weeks after the initiation of treatment. Subjects were classified as improved or stable based on their GROC scores. RESULTS: The area under the curve (AUC) for the VISA-A was 0.97 and a MCID of 6.5 points was identified. The AUC for the LEFS was 0.97 and a MCID of 12 points was identified. CONCLUSION: The VISA-A and LEFS are both useful outcome measures to assess response in patients with IAT. LEVEL OF EVIDENCE: 3.
Authors: J M Robinson; J L Cook; C Purdam; P J Visentini; J Ross; N Maffulli; J E Taunton; K M Khan Journal: Br J Sports Med Date: 2001-10 Impact factor: 13.800
Authors: Marianne Beninato; Kathleen M Gill-Body; Sara Salles; Paul C Stark; Randie M Black-Schaffer; Joel Stein Journal: Arch Phys Med Rehabil Date: 2006-01 Impact factor: 3.966
Authors: Robert J de Vos; Adam Weir; Hans T M van Schie; Sita M A Bierma-Zeinstra; Jan A N Verhaar; Harrie Weinans; Johannes L Tol Journal: JAMA Date: 2010-01-13 Impact factor: 56.272
Authors: Jackson R Staggers; Kenneth Smith; Cesar de C Netto; Sameer Naranje; Krishna Prasad; Ashish Shah Journal: Int Orthop Date: 2018-02-16 Impact factor: 3.075
Authors: Thomas A Meijers; Adel Aminian; Marleen van Wely; Koen Teeuwen; Thomas Schmitz; Maurits T Dirksen; Sudhir Rathore; René J van der Schaaf; Paul Knaapen; Joseph Dens; Juan F Iglesias; Pierfrancesco Agostoni; Vincent Roolvink; Miguel E Lemmert; Renicus S Hermanides; Niels van Royen; Maarten A H van Leeuwen Journal: J Am Heart Assoc Date: 2022-01-13 Impact factor: 6.106